1996
DOI: 10.1089/hum.1996.7.1-23
|View full text |Cite
|
Sign up to set email alerts
|

Loss of Tumorigenicity and Increased Immunogenicity Induced by Interleukin-10 Gene Transfer in B16 Melanoma Cells

Abstract: Because interleukin-10 (IL-10) has potent immunosuppressive and anti-inflammatory properties and is produced by some cancers, we hypothesized that its production might play a role in carcinogenesis by inhibiting adequate antitumoral immune responses. To test this hypothesis, retroviral vectors containing the IL-10 cDNA were generated and used to infect B16F1 melanoma cells that were injected subcutaneously in syngeneic mice. Surprisingly, IL-10 gene transfer resulted in a loss of tumorigenicity that was propor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
51
0

Year Published

1997
1997
2014
2014

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 76 publications
(53 citation statements)
references
References 36 publications
2
51
0
Order By: Relevance
“…Of note, GM-CSF-, IL-5-, IL-6-, and TNF-␣-expressing cells caused significant side effects (14,31). To date, only IL-2 and IL-10 have been reported to induce complete regression of transduced B16 tumors in vivo (14,15). In our study, syngeneic mice injected with B16F1-IL-21 or MethA-IL-21 tumor cells did not develop any clinically overt tumor for a period of Ͼ41 wk after tumor inoculation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Of note, GM-CSF-, IL-5-, IL-6-, and TNF-␣-expressing cells caused significant side effects (14,31). To date, only IL-2 and IL-10 have been reported to induce complete regression of transduced B16 tumors in vivo (14,15). In our study, syngeneic mice injected with B16F1-IL-21 or MethA-IL-21 tumor cells did not develop any clinically overt tumor for a period of Ͼ41 wk after tumor inoculation.…”
Section: Discussionmentioning
confidence: 99%
“…Studies with genetically modified tumor cells have highlighted the participation of several types of cells, including neutrophils, eosinophils, mast cells, lymphocytes, and NK cells in tumor rejection (15)(16)(17)(18)(19)(20). To determine the relative roles of lymphocytes in the rejection of IL-21-transduced tumor cells, equal numbers (10 5 ) of B16F1-IL-21 or control B16F1-GFP cells were injected into T and B cell-deficient (SCID) mice.…”
Section: Il-21 Requires Both Innate and Adaptive Immunity In Tumor Rementioning
confidence: 99%
“…Tumor cells engineered to express IL-10 were rejected in immunocompetent hosts (31). Moreover, transplantable tumors injected into mice genetically engineered to express human IL-10 in myeloid cells (IL-10TG) were rejected, which was dependent on the presence of CD8 þ T cells in the host (32).…”
Section: Il-10 Stimulates Cytotoxicity Of Tumor-resident Cd8 þ T Cellsmentioning
confidence: 99%
“…[4][5][6] However, a large body of evidence in different animal tumor models opposes this theory, showing that IL-10 can favor immune-mediated cancer rejection. [7][8][9][10][11][12][13][14] In humans, the knowledge on IL-10's role in tumor immunology is scarce. In the search for a cytokine pattern that could predict tumor response to IL-2/peptide-based melanoma patient vaccination, 15 we studied cytokine mRNA abundance in fine-needle aspirate material from metastatic lesions by using quantitative real-time PCR.…”
Section: Introductionmentioning
confidence: 99%